Bharat Immunologicals & Biologicals Valuation
Is 524663 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 524663 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 524663 (₹31.28) is trading below our estimate of fair value (₹37.8)
Significantly Below Fair Value: 524663 is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 524663?
Other financial metrics that can be useful for relative valuation.
What is 524663's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | ₹1.34b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 26x |
Enterprise Value/EBITDA | -10x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 524663's PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 6.2x | ||
NIRMAN Nirman Agri Genetics | 4.4x | n/a | ₹1.3b |
532039 Zenotech Laboratories | 10.1x | n/a | ₹3.8b |
PANACEABIO Panacea Biotec | 1.5x | n/a | ₹8.4b |
532041 Hindustan Bio Sciences | 8.6x | n/a | ₹85.9m |
524663 Bharat Immunologicals & Biologicals | 17.7x | n/a | ₹1.3b |
Price-To-Sales vs Peers: 524663 is expensive based on its Price-To-Sales Ratio (17.7x) compared to the peer average (6.2x).
Price to Earnings Ratio vs Industry
How does 524663's PE Ratio compare vs other companies in the Asian Biotechs Industry?
Price-To-Sales vs Industry: 524663 is expensive based on its Price-To-Sales Ratio (17.7x) compared to the Asian Biotechs industry average (9.4x).
Price to Sales Ratio vs Fair Ratio
What is 524663's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 17.7x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate 524663's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.